PharVision Advisers’s Cytokinetics CYTK Stock Holding History

PharVision Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,765	Closed	-$207K	–	752
2025 Q3	$207K	Buy	+3,765	New	+$155K	0.12%	487

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PharVision Advisers's CYTK Position: Q4 2025 in Review

PharVision Advisers sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 3,765 shares — an estimated $207K sold.

PharVision Advisers first reported a position in CYTK in Q3 2025 and held it in 1 quarter. The position peaked at $207K in Q3 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

PharVision Advisers reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 3,765 Cytokinetics shares in Q4 2025, an estimated $207K.
PharVision Advisers first reported a position in Cytokinetics in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Cytokinetics position peaked at $207K in Q3 2025.
430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.